Unicancer

This study tested whether changing hormone therapy (from an aromatase inhibitor to fulvestrant) when a blood test detects a specific genetic change (ESR1 mutation) can help women with advanced, hormone-sensitive breast cancer live longer without their cancer growing. Over 1,000 p…

This study tested whether a stronger chemotherapy combination (mFOLFIRINOX) is better than the standard one (mFOLFOX) at preventing cancer from coming back in people with high-risk stage III colon cancer after surgery. About 792 adults aged 18 to 74 took part. The main goal was t…

This study tested whether adding the immunotherapy drug durvalumab to standard chemoradiation helps people with esophageal cancer that cannot be removed by surgery. 112 patients took part. The main goal was to see if the combination slowed cancer growth or improved survival. Whil…

This study looked at whether combining two chemotherapy drugs (gemcitabine and paclitaxel) helps people with advanced pancreatic cancer live longer than using just one drug (gemcitabine) alone. The 211 participants had already tried a standard treatment called FOLFIRINOX, which e…

This study tested a drug called tislelizumab in 50 people with advanced liver cancer who also have moderate liver damage (Child-Pugh B). The goal was to see if the drug could shrink tumors. Tislelizumab works by helping the immune system attack cancer cells. The study took place …

This study looked at 132 people with oral or throat cancer who needed part of their jaw removed and rebuilt using a bone from their leg. Half had standard surgery, and half had 3D virtual planning before the operation. The main goal was to see if virtual planning improved quality…

This study looked at how women aged 65 and older with early-stage breast cancer choose between three treatment options after surgery: standard radiation therapy, a single dose of radiation during surgery, or no radiation at all. Researchers wanted to understand what factors influ…